Loading...
Projects / Programmes source: ARIS

Genes, hormones and personality changes in metabolic disorders

Periods
Research activity

Code Science Field Subfield
3.07.00  Medical sciences  Metabolic and hormonal disorders   
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B000  Biomedical sciences   

Code Science Field
3.02  Medical and Health Sciences  Clinical medicine 
3.01  Medical and Health Sciences  Basic medicine 
Keywords
osteoporosis, polycystic ovary syndrome,diabetes, primary aldosteronism
Evaluation (rules)
source: COBISS
Points
7,824.43
A''
847.43
A'
2,978.5
A1/2
4,680.17
CI10
16,985
CImax
1,095
h10
53
A1
26.52
A3
2.55
Data for the last 5 years (citations for the last 10 years) on April 15, 2024; A3 for period 2018-2022
Data for ARIS tenders ( 04.04.2019 – Programme tender , archive )
Database Linked records Citations Pure citations Average pure citations
WoS  567  18,118  17,242  30.41 
Scopus  544  20,958  20,010  36.78 
Researchers (30)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  26227  Manja Cedilnik    Technical associate  2019 - 2024 
2.  38672  PhD Klemen Čamernik  Pharmacy  Researcher  2021  21 
3.  50053  PhD Simona Ferjan  Metabolic and hormonal disorders  Researcher  2020 - 2024  92 
4.  55258  PhD Nina Franko  Pharmacy  Researcher  2021  19 
5.  57412  Danijela Herga  Pharmacy  Researcher  2022 - 2024 
6.  18372  PhD Andrej Janež  Metabolic and hormonal disorders  Head  2019 - 2024  667 
7.  32347  PhD Mojca Jensterle Sever  Metabolic and hormonal disorders  Researcher  2019 - 2024  566 
8.  50226  PhD Jasna Klen  Metabolic and hormonal disorders  Researcher  2019 - 2024  79 
9.  15783  PhD Tomaž Kocjan  Metabolic and hormonal disorders  Researcher  2019 - 2024  518 
10.  38167  PhD Klemen Kodrič  Metabolic and hormonal disorders  Junior researcher  2019  15 
11.  53673  Nika Kržišnik  Pharmacy  Researcher  2022 - 2024  39 
12.  34385  PhD Jasna Lojk  Metabolic and hormonal disorders  Researcher  2021 - 2024  68 
13.  19649  PhD Marija Nika Lovšin  Microbiology and immunology  Researcher  2019 - 2022  124 
14.  28865  PhD Mojca Lunder  Cardiovascular system  Researcher  2019 - 2024  144 
15.  12189  PhD Janja Marc  Metabolic and hormonal disorders  Researcher  2019 - 2024  712 
16.  57310  Ines Medved Palčar  Pharmacy  Researcher  2022 - 2024 
17.  54655  Ana Munda  Medical sciences  Junior researcher  2020 - 2024  18 
18.  57511  Marija Novak    Technical associate  2023 - 2024 
19.  39277  Evelina Oltra    Technical associate  2019 - 2024 
20.  18154  PhD Barbara Ostanek  Metabolic and hormonal disorders  Researcher  2019 - 2024  188 
21.  33759  Mirela Ožura    Technical associate  2019 - 2024 
22.  24466  PhD Draženka Pongrac Barlovič  Metabolic and hormonal disorders  Researcher  2019 - 2024  341 
23.  22657  PhD Irena Prodan Žitnik  Metabolic and hormonal disorders  Researcher  2019 - 2024  48 
24.  58036  Žana Rus  Metabolic and hormonal disorders  Junior researcher  2023 - 2024 
25.  28525  PhD Aleš Skvarča  Metabolic and hormonal disorders  Researcher  2019 - 2022  141 
26.  21971  Elizabeta Stepanovič    Technical associate  2019 - 2024  11 
27.  12151  PhD Vilma Urbančič-Rovan  Metabolic and hormonal disorders  Researcher  2019 - 2024  219 
28.  53726  Lucija Ana Vrščaj  Metabolic and hormonal disorders  Junior researcher  2019 - 2024  31 
29.  32306  PhD Janja Zupan  Metabolic and hormonal disorders  Researcher  2019 - 2021  110 
30.  19635  Barbara Žargaj    Technical associate  2019 - 2024 
Organisations (2)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0312  University Medical Centre Ljubljana  Ljubljana  5057272000  77,351 
2.  0787  University of Ljubljana, Faculty of Pharmacy  Ljubljana  1626973  17,155 
Abstract
In the last two decades our programme P3-0298 is based on activities and achievements in basic, laboratory and clinical research in the field of chronic metabolic disorders such as osteoporosis and bone metabolism, polycystic ovary syndrome (PCOS), diabetes type 2 and insulin resistance as a common component of the last two disorders. During 20 years we published more than 150 per-review papers in the field and participated in discovery of important bone-related genes like osteoprotegerin, RANKL, ADRA2A and the role of immune system, oxidative stress and epigenetic factors like microRNAs in the pathogenesis of osteoporosis. The overall objective of the research program is to improve osteoporosis management In the field of PCOS we intend to continue in searching improvements in therapy of this condition. We are the first to use incretin based therapy in obese women with high metabolic risk profile. Based on our reaserch in this patient population, liraglutide obtained registration as antiobesity drug.Our preliminary results with GLP-1 agonists are encouraging in the filed of reproduction, where we have developed our own short term therapeutic strategy to improve treatment outcomes in obese metabolically high risk patients procedeeing in vitro fertilization (IVF). In the field of adrenal gland we are searching for laboratory and clinical predictors in a cohort of patients with bilateral primary aldosteronism who can proceed with a treatment without chatetrization of adrenal veins. Together with other established European centers we have published important study on treatment outcomes in this patient population.
Significance for science
Studies of the genetic background of osteoporosis yielded a large amount of useful data that can be used in clinical work as well as clues for basic research. Our group contributed to this field and participated in discovery of important bone-related genes like osteoprotegerin, RANKL, ADRA2A and the role of immune system, oxidative stress and epigenetic factors like microRNAs in the pathogenesis of osteoporosis. In the field of PCOS, our short term treatment strategy with incretin based therapy improves fertility potential and reduces conversion rate from prediabetes to diabetes in obese women with high metabolic risk profile.
Significance for the country
Our programme is based on the research in the field of chronic metabolic disorders such as osteoporosis and bone metabolism, polycystic ovary syndrome (PCOS), diabetes type 2 and insulin resistance. These are the most prevalent endocrinological diseases and represent big burden and costs for our society. The aim of our resarch is to improve prevention strategy and treatment outcomes of these diseases.
Most important scientific results Interim report
Most important socioeconomically and culturally relevant results Interim report
Views history
Favourite